Startups
'It's awful': Tyro scrambles to fix outages, hits back at short seller claims
ASX listed payments technology company Tyro has hit back at 'false' short seller claims about its technical problems as it continues to scramble to fix outages which have continued for two weeks.
- by Cara Waters
Latest
Pot stocks riding high on Biden optimism
Research-focused cannabis stocks are hoping a new US president will expand their market opportunities.
- by Emma Koehn
ACCC considers legal action after Google completes $2.7 billion Fitbit deal
Australia's competition watchdog is continuing its investigation into Google's acquisition of fitness tracking pioneer Fitbit despite the sale completing on Friday.
- by Cara Waters
Australia's 'most unreliable fintech': Tyro targeted by short seller as outage continues
Beleaguered payments technology company Tyro is being targeted by short seller Viceroy Research which claims Tyro's technology problems laid bare in an 11 day long outage are worse than reported.
- by Cara Waters
ASX market darling Pro Medicus surges on breakthrough US contract
The $3.7 billion medical technology operator is inking big contracts as the pandemic rages in North America.
- by Emma Koehn
'Woefully inadequate': Tyro faces legal proceedings as outage problems grow
In an update to the Australian Securities Exchange on Wednesday Tyro reported the outages had impacted 30 per cent of its customers.
- by Cara Waters
Exclusive
Banking products
Xinja investors told shares worth 'close to, or actually, zero'
Xinja shareholders are bracing for the worst after being told their shares could be worth nothing.
- by Charlotte Grieve
'What they did was justified': Amazon's local customers back move to boot Parler
Australian customers of web hosting giant Amazon have backed its decision to kick controversial social networking platform Parler off its servers.
- by Cara Waters
Embattled payments provider Tyro defends outage response
Embattled payments technology company Tyro has defended its response to week long outages after its terminals were 'bricked' leaving businesses unable to process payments.
- by Cara Waters
Mesoblast holds out hope for heart failure drug
Shares in the stem cell treatment developer regained some ground after a horror end to 2020.
- by Emma Koehn
'All Australians will benefit': Prepare for a research boom in 2021
The pandemic and new policies have created the perfect storm for ASX-listed companies that collectively spend more than a billion dollars a year on research.
- by Emma Koehn